Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes

References

• ShawRJCantleyLCRas, PI(3)K and mTOR signalling controls tumour cell growthNature200644142443016724053
   PubMed Web of Science ®Google Scholar
• HaraKYonezawaKWengQPAmino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanismJ Biol Chem199827314484144949603962
   PubMed Web of Science ®Google Scholar
• BrugarolasJLeiKHurleyRLRegulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complexGenes Dev2004182893290415545625
   PubMed Web of Science ®Google Scholar
• ShawRJBardeesyNManningBDThe LKB1 tumor suppressor negatively regulates mTOR signalingCancer Cell20046919915261145
   PubMed Web of Science ®Google Scholar
• CantleyLCThe phosphoinositide 3-kinase pathwayScience20022961655165712040186
   PubMed Web of Science ®Google Scholar
• GhayadSECohenPAInhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patientsRecent Pat Anticancer Drug Discov20105295719751211
   PubMed Web of Science ®Google Scholar
• YamnikRLHolzMKmTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylationFEBS Lett201058412412819925796
   PubMed Web of Science ®Google Scholar
• YamnikRLDigilovaADavisDCS6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferationJ Biol Chem20092846361636919112174
   PubMed Web of Science ®Google Scholar
• DanceyJmTOR signaling and drug development in cancerNat Rev Clin Oncol2010720921920234352
   PubMed Web of Science ®Google Scholar
• DemetriGDChawlaSPRay-CoquardIResults of an international randomized Phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapyJ Clin Oncol2013312485249223715582
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health Available from: http://Clinicaltrials.govAccessed December 12, 2013
   Google Scholar
• ChanSScheulenMEJohnstonSPhase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancerJ Clin Oncol2005235314532215955899
   PubMed Web of Science ®Google Scholar
• CarpenterJTRochéHCamponeMRandomized 3-arm, Phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancerJ Clin Oncol200523564
   Web of Science ®Google Scholar
• WolffACLazarAABondarenkoIRandomized Phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancerJ Clin Oncol20133119520223233719
   PubMed Web of Science ®Google Scholar
• BaselgaJSemiglazovVvan DamPPhase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancerJ Clin Oncol2009272630263719380449
   PubMed Web of Science ®Google Scholar
• BachelotTBourgierCCropetCRandomized Phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO studyJ Clin Oncol2012302718272422565002
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med201236652052922149876
   PubMed Web of Science ®Google Scholar
• YardleyDANoguchiSPritchardKIEverolimus plus exemes-tane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysisAdv Ther20133087088424158787
   PubMed Web of Science ®Google Scholar
• ChiaSGradisharWMauriacLDouble-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECTJ Clin Oncol2008261664167018316794
   PubMed Web of Science ®Google Scholar
• JohnstonSRKilburnLSEllisPFulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, Phase 3 randomised trialLancet Oncol20131498999823902874
   PubMed Web of Science ®Google Scholar
• CamponeMBachelotTGnantMEffect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 studyEur J Cancer2013492621263223735704
   PubMed Web of Science ®Google Scholar
• PaikSShakSTangGA multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerN Engl J Med20043512817282615591335
   PubMed Web of Science ®Google Scholar
• MorrowPKWulfGMEnsorJPhase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapyJ Clin Oncol2011293126313221730275
   PubMed Web of Science ®Google Scholar
• AndreFCamponeMO’ReganRPhase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumabJ Clin Oncol2010285110511520975068
   PubMed Web of Science ®Google Scholar
• HurvitzSADalencFCamponeMA Phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overex-pressing advanced breast cancer that progressed during prior trastuzumab and taxane therapyBreast Cancer Res Treat201314143744624101324
   PubMed Web of Science ®Google Scholar
• JerusalemGFasoloADierasVPhase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancerBreast Cancer Res Treat201112544745521107682
   PubMed Web of Science ®Google Scholar
• O’ReganROzgurogluMAndreFPhase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3)J Clin Oncol201331Suppl Abstr 505
   Google Scholar
• WalshSFlanaganLQuinnCmTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumorsBreast20122117818221963359
   PubMed Web of Science ®Google Scholar
• UengSHChenSCChangYSPhosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomasInt J Clin Exp Pathol2012580681323071863
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature2012490617023000897
   PubMed Web of Science ®Google Scholar
• MayerIAJovanovicBAbramsonVGA randomized Phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNCB)Poster PD1-6 presented at the San Antonio Breast Cancer SymposiumDecember 10–14, 2013San Antonio, TX, USA
   Google Scholar
• HuoberJFaschingPAHanuschCNeoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) +/− bevacizumab – results of the randomised GeparQuinto study (GBG 44)Eur J Cancer2013492284229323541564
   PubMed Web of Science ®Google Scholar
• BurrisHAIIILebrunFRugoHSHealth-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the Phase 3, randomized, controlled, BOLERO-2 trialCancer20131191908191523504821
   PubMed Web of Science ®Google Scholar
• RavaudAUrvaSRGroschKRelationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncologyEur J Cancer20145048649524332451
   PubMed Web of Science ®Google Scholar
• O’DonnellAFaivreSBurrisHAIIIPhase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumorsJ Clin Oncol2008261588159518332470
   PubMed Web of Science ®Google Scholar
• TaberneroJRojoFCalvoEDose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a Phase I tumor pharmacodynamic study in patients with advanced solid tumorsJ Clin Oncol2008261603161018332469
   PubMed Web of Science ®Google Scholar
• TreilleuxIArnedosMCropetCPredictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): final results of the TAMRAD trial translational studyJ Clin Oncol201331Suppl Abstr 510
   Google Scholar
• HortobagyiGPiccart-GebhartMRugoHCorrelation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2J Clin Oncol201331 abstract LBA509
   Google Scholar
• RugoHCamponeMGnantMBOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancerJ Clin Oncol201331Suppl Abstr 152
   Google Scholar
• JerusalemGAndreFChenDEvaluation of everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway: exploratory biomarker observations from the BOLERO-3 trialEur J Cancer201349Suppl 3PS8
   Google Scholar
• DonASZhengXFRecent clinical trials of mTOR-targeted cancer therapiesRev Recent Clin Trials20116243520868343
   PubMedGoogle Scholar
• CybulskiNHallMNTOR complex 2: a signaling pathway of its ownTrends Biochem Sci20093462062719875293
   PubMed Web of Science ®Google Scholar
• SunSYRosenbergLMWangXActivation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibitionCancer Res2005657052705816103051
   PubMed Web of Science ®Google Scholar
• WanXHarkavyBShenNGroharPHelmanLJRapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanismOncogene2007261932194017001314
   PubMed Web of Science ®Google Scholar